This being said, the search for FLT3, IDH1, and IDH2 mutations is now mandatory for physicians who cure AML, due to the implications that these alterations may have on clinical patients’ management, and to the availability of these drugs not only in the setting they were approved for, but also in more recently designed clinical trials (Table 2). This evidence concerns the gene IDH1 and acute myeloid leukemia.